Insider Transactions in Q1 2022 at Travere Therapeutics, Inc. (TVTX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2022
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,832
-2.93%
|
$130,464
$27.84 P/Share
|
|
Jan 31
2022
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,813
-2.84%
|
$129,951
$27.4 P/Share
|
|
Jan 31
2022
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
37,848
+18.25%
|
-
|
|
Jan 31
2022
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,238
-3.17%
|
$33,426
$27.4 P/Share
|
|
Jan 31
2022
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,840
+20.11%
|
-
|
|
Jan 31
2022
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,125
-1.64%
|
$30,375
$27.4 P/Share
|
|
Jan 31
2022
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,840
+12.57%
|
-
|
|
Jan 31
2022
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,125
-2.43%
|
$30,375
$27.4 P/Share
|
|
Jan 31
2022
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
9,840
+17.51%
|
-
|
|
Jan 31
2022
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
1,350
-2.99%
|
$36,450
$27.4 P/Share
|
|
Jan 31
2022
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
9,840
+17.9%
|
-
|
|
Jan 31
2022
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
798
-2.13%
|
$20,748
$26.51 P/Share
|
|
Jan 31
2022
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+18.96%
|
-
|
|
Jan 24
2022
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,873
-5.64%
|
$188,952
$24.98 P/Share
|
|
Jan 24
2022
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,063
-6.59%
|
$49,512
$24.98 P/Share
|
|
Jan 24
2022
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,250
-5.99%
|
$54,000
$24.98 P/Share
|
|
Jan 24
2022
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,875
-3.1%
|
$45,000
$24.98 P/Share
|
|
Jan 24
2022
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
1,875
-4.88%
|
$45,000
$24.98 P/Share
|
|
Jan 24
2022
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
934
-3.16%
|
$22,416
$24.58 P/Share
|
|
Jan 11
2022
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,500
-19.32%
|
$202,500
$27.4 P/Share
|
|
Jan 11
2022
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,500
-6.11%
|
$67,500
$27.4 P/Share
|
|
Jan 11
2022
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
5,000
-11.75%
|
$135,000
$27.4 P/Share
|
|
Jan 10
2022
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+16.19%
|
-
|
|
Jan 10
2022
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.89%
|
-
|
|
Jan 10
2022
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.52%
|
-
|
|
Jan 05
2022
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-4.16%
|
$375,000
$30.16 P/Share
|
|
Jan 04
2022
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,832
-3.08%
|
$144,960
$30.43 P/Share
|
|
Jan 01
2022
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|